About Us

Our History

WuXi PharmaTech was registered in the city of Wuxi, Jiangsu and operated in Shanghai
WuXi PharmaTech started synthetic chemistry services
WuXi PharmaTech started manufacturing process development services
WuXi PharmaTech started manufacturing services for research and development
WuXi PharmaTech started bio-analytical services
WuXi PharmaTech started antibody discovery and process development services
WuXi PharmaTech started toxicology and formulation services
The Tianjin site of WuXi PharmaTech was put into operation and it was among the leading R&D bases of chemical medicines in China then
WuXi PharmaTech traded on the New York Stock Exchange under the ticker symbol "NYSE:WX"
WuXi PharmaTech set up "Life Science and Chemistry Awards", aiming to stimulate early-stage innovation and promote excellence in life sciences and clinical research
WuXi PharmaTech acquired AppTec Laboratory Services, with locations in Minnesota, Pennsylvania and Georgia. The Company has been renamed WuXi AppTec since then.
WuXi AppTec opened a toxicology facility in Suzhou, which became the most important base of toxicology services
SynTheAll Pharmaceutical (STA) opened a large-scale manufacturing facility in Jinshan District, Shanghai
WuXi AppTec acquired Medkey, expanding to clinical development and registration services
The R&D and manufacturing site in the city of Wuxi was put into operation
Wuhan site was put into operation, and it became the key of WuXi AppTec's strategic network in central and western China
WuXi AppTec opened a new facility in Philadelphia, Pennsylvania, strengthening R&D and production services of CAR-T therapies and other immunotherapies
WuXi AppTec Laboratory Testing Division expanded with acquisition of XenoBiotic Laboratories in Plainsboro, New Jersey, bolstering LTD's bioanalytical and DMPK/ADME services for U.S. customers
WuXi AppTec launched medical device testing services in China
WuXi AppTec acquired Crelux, enhancing WuXi AppTec's structure-based drug discovery capabilities in Europe
STA began operations at a new, fully integrated R&D and cGMP manufacturing site in Changzhou
WuXi AppTec set up Advanced Therapy Unit in Philadelphia, Pennsylvania, enhancing U.S.-based cell and gene therapies
WuXi AppTec acquired HD Biosciences in San Diego, California, strengthening U.S. biology R&D capacity and capability
WuXi AppTec acquired ResearchPoint Global in Austin, Texas, expanding U.S. clinical research capabilities
WuXi AppTec built up its Life Science Industry Park in Chengdu
WuXi AppTec announced listing of Initial Public Offering of Common Stock on the Shanghai Stock Exchange (stock code: 603259.SH)
WuXi AppTec listed H shares on the Hong Kong Stock Exchange (stock code: 2359.HK)
The first WuXi Healthcare Forum held in Shanghai
WuXi AppTec acquired Pharmapace in San Diego, California, to enhance biometrics services for clinical development
WuXi STA oligonucleotide large-scale manufacturing facility was put into operation
WuXi AppTec hosted a series of online COVID-19 forums to strengthen the collaboration across the global healthcare industry
The Chengdu site of WuXi AppTec was put into operation
WuXi Advanced Therapies expanded Philadelphia campus with new state-of-the-art testing laboratory
WuXi STA purchased Bristol Myers Squibb manufacturing facility in Couvet, Switzerland
WuXi AppTec acquired OXGENE to further strengthen Cell and Gene Therapy service offerings for global customers
WuXi STA announced to build new pharmaceutical manufacturing campus in Middletown, Delaware
WuXi ATU opened new facility in Philadelphia, tripling testing capacity to support global customers
WuXi STA opened new large-scale oligonucleotide and peptide manufacturing facility
WuXi AppTec planned to build a new site in Singapore, better serving global partners and advancing healthcare innovation